Beijing VDJBio Co.
Latest round
- Series C
Last raised
- Jun 2023
Total raised
- Undisclosed
Investors
- 11
About Beijing VDJBio Co.
, Ltd. is a biotechnology company that focuses on the research and development of innovative antibody drugs for autoimmune diseases. Ziqiang Li, the founder and CEO of the company, used to be the director of the Cell Biology Department of Novo Nordisk China R&D Center. The company's main products include IL-6R antibody and CTLA-4-Ig, etc. CTLA-4-Ig fusion protein is used to inhibit T cell activation. Its products are used in the treatment of autoimmune diseases and inflammation, among other fields.
Who invested in Beijing VDJBio Co.
11 investors across 3 rounds
See all investors in Beijing VDJBio Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Beijing VDJBio Co.
Who invested in Beijing VDJBio Co.?
Beijing VDJBio Co. has 11 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Beijing VDJBio Co. raised?
Beijing VDJBio Co. has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Beijing VDJBio Co. last raise money?
Beijing VDJBio Co.'s most recent round on record is a Series C, in Jun 2023.
What does Beijing VDJBio Co. do?
Beijing VDJBio Co. is a biotechnology company.
Where is Beijing VDJBio Co. headquartered?
Beijing VDJBio Co. is headquartered in Beijing, China.
Which VCs invest in companies like Beijing VDJBio Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Beijing VDJBio Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Beijing VDJBio Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.